EGFR and non-small cell lung carcinoma: Moreover, we provided insights into the changes to the TME after long-term exposure to continuous targeted therapy using erlotinib, as well as after ongoing simultaneous long-term administration of targeted therapy and ICB in EGFR-driven NSCLC.